XML 67 R45.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue - Additional Information (Details) $ in Thousands | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2023 dose | Jul. 31, 2020 USD ($) dose | Jun. 30, 2020 USD ($) dose | May 31, 2020 USD ($) | Dec. 31, 2022 USD ($) dose | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Nov. 30, 2022 dose | Nov. 18, 2022 dose | Jul. 31, 2022 USD ($) dose | Mar. 31, 2022 USD ($) | Sep. 30, 2021 dose | Oct. 22, 2020 dose
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Billed contracts receivable |  |  |  |  | $ 53,800 | $ 419,700 |  |  |  |  |  |  |
Unbilled contracts receivable |  |  |  |  | 28,600 | 35,300 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 549,551 | 1,595,472 | $ 273,228 |  |  |  |  |  |
Purchase agreement, number of vaccine doses | dose |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000
Collaboration agreement upfront payment amount |  |  |  |  | 819,000 |  |  |  |  |  |  |  |
Total revenue |  |  |  |  | 1,981,872 | 1,146,290 | 475,598 |  |  |  |  |  |
Sales-Based Royalties |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  | $ 9,000 | 178,600 |  |  |  |  |  |  |
Amended and Restated UK Supply Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |
Amended and Restated UK Supply Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  |  |  |  | 7,500,000 |  | 15,000,000 |  |  |
Gavi Advance Purchase Agreement SIIPL |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  | 1,100,000,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | 350,000 |  |  |  |  |  |  |
Remaining performance obligation, variable consideration amount |  |  |  |  |  |  |  |  |  |  | $ 350,000 |  |
Gavi Advance Purchase Agreement- COVAX Facility |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  |  |  |  |  | 350,000,000 |  |  |  |
Purchase agreement, number of vaccine doses | dose |  |  |  |  |  |  |  |  | 2,000,000 |  |  |  |
Collaboration agreement upfront payment amount |  |  |  |  | $ 697,400 |  |  |  |  |  |  |  |
Joint Committee on Vaccination and Immunization (JCVI) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  |  |  |  |  |  | 44,000,000 |  |  |
Deferred revenue |  |  |  |  | 112,500 |  |  |  |  |  |  |  |
Collaboration agreement upfront payment amount |  |  |  |  | $ 112,500 |  |  |  |  | $ 225,000 |  |  |
European Commissions ("EC") |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  | 100,000,000 |  |  |  |  |  |  |  |
Purchase agreement, number of vaccine doses | dose |  |  |  |  | 63,000,000 |  |  |  |  |  |  |  |
Additional purchase option, number of doses | dose |  |  |  |  | 200,000,000 |  |  |  |  |  |  |  |
Number of doses, cancelled | dose |  |  |  |  | 7,000,000 |  |  |  |  |  |  |  |
European Commissions ("EC") | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses | dose | 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |
European Commissions ("EC") | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  | 20,000,000 |  |  |  |  |  |  |  |
European Commissions ("EC") | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  | 100,000,000 |  |  |  |  |  |  |  |
USG Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase agreement, number of vaccine doses | dose |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |
Number of doses | dose |  | 100,000,000 |  |  |  |  |  |  |  |  |  |  |
Research and development arrangement, contract ceiling |  | $ 1,800,000 |  |  |  |  |  |  |  |  |  |  |
USG Agreement | Government Contract |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer |  | $ 1,750,000 |  |  | $ 1,400,000 |  |  |  |  |  |  |  |
Research and development arrangement, contract to perform for others, contract remaining |  |  |  |  | 416,000 |  |  |  |  |  |  |  |
DoD Contract |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase agreement, number of vaccine doses | dose |  |  |  |  |  |  |  |  |  | 200,000 |  |  |
Additional purchase option, number of doses | dose |  |  |  |  |  |  |  |  |  | 9,800,000 |  |  |
Number of doses | dose |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |
Performance obligation, customer status, period |  |  | 5 years |  |  |  |  |  |  |  |  |  |
DoD Contract | Government Contract |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer |  |  | $ 45,700 |  |  |  |  |  |  |  |  |  |
Coalition for Epidemic Preparedness Innovations ("CEPI") |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contract to perform for others funding |  |  |  | $ 399,500 |  |  |  |  |  |  |  |  |
Contract to perform for others grant |  |  |  | 257,000 |  |  |  |  |  |  |  |  |
Contract to perform for others forgivable no interest term loans |  |  |  | $ 142,500 |  |  |  |  |  |  |  |  |
CEPI Grant Funding |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from contract with customer |  |  |  |  | 358,600 | $ 358,600 |  |  |  |  |  |  |
Takeda Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of doses to be distributed | dose |  |  |  |  |  |  |  |  |  |  |  | 150,000,000 |
Milestone payment recognized |  |  |  |  | 20,000 |  | $ 20,000 |  |  |  |  |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining performance obligation to be satisfied |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
Remaining performance obligation, expected timing of satisfaction, period |  |  |  |  | 1 year |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement Upfront Payment Amount + References No definition available. + Details
Name: | nvax_CollaborationAgreementUpfrontPaymentAmount
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number Of Doses Of Vaccine Candidate + References No definition available. + Details
Name: | nvax_NumberOfDosesOfVaccineCandidate
Namespace Prefix: | nvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Doses Of Vaccine Candidate, Additional Purchase Option + References No definition available. + Details
Name: | nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
Namespace Prefix: | nvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Doses, To Be Distributed + References No definition available. + Details
Name: | nvax_NumberOfDosesToBeDistributed
Namespace Prefix: | nvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase Agreement, Number of Doses, Cancelled + References No definition available. + Details
Name: | nvax_PurchaseAgreementNumberOfDosesCancelled
Namespace Prefix: | nvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchase Agreement, Number Of Vaccine Doses + References No definition available. + Details
Name: | nvax_PurchaseAgreementNumberOfVaccineDoses
Namespace Prefix: | nvax_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research and Development Arrangement, Contract to Perform for Others, Contract Ceiling + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractCeiling
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research and Development Arrangement, Contract to Perform for Others, Contract Remaining + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersContractRemaining
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research And Development Arrangement Contract To Perform For Others Forgivable No Interest Term Loans + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersForgivableNoInterestTermLoans
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement Contract To Perform For Others Funding + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersFunding
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement Contract To Perform For Others Grant + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentArrangementContractToPerformForOthersGrant
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Contract With Customer Commitment + References No definition available. + Details
Name: | nvax_RevenueFromContractWithCustomerCommitment
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Customer Status, Period + References No definition available. + Details
Name: | nvax_RevenueRemainingPerformanceObligationCustomerStatusPeriod
Namespace Prefix: | nvax_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | nvax_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406 + Details
Name: | us-gaap_BilledContractReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406 + Details
Name: | us-gaap_UnbilledContractsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=nvax_SalesBasedRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=nvax_AmendedAndRestatedUKSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementSIIPLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_GaviAdvancePurchaseAgreementCOVAXFacilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_JointCommitteeOnVaccinationAndImmunizationJCVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_EuropeanCommissionsECMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_USGovernmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_DoDContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_CoalitionForEpidemicPreparednessInnovationsCEPIAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_CEPIGrantFundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nvax_TakedaArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |